Ionis Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.

CEO

Brett P. Monia

CEOBrett P. Monia

Employees

1,402

Employees1,402

Headquarters

Carlsbad, California

HeadquartersCarlsbad, California

Founded

1989

Founded1989

Employees

1,402

Employees1,402

IONS Key Statistics

Market cap

12.25B

Market cap12.25B

Price-Earnings ratio

-30.04

Price-Earnings ratio-30.04

Dividend yield

—

Dividend yield—

Average volume

1.60M

Average volume1.60M

High today

—

High today—

Low today

—

Low today—

Open price

$74.91

Open price$74.91

Volume

0.00

Volume0.00

52 Week high

$86.74

52 Week high$86.74

52 Week low

$28.79

52 Week low$28.79

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $74.09. The company's market cap stands at 12.25B, with a P/E ratio of -30.04.

During the trading day, Ionis Pharmaceuticals(IONS) stock saw an opening price of $74.91, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.6M.

The stock's 52-week range extends from a low of $28.79 to a high of $86.74.

IONS News

TipRanks 24h

Ionis Pharmaceuticals price target lowered to $108 from $110 at TD Cowen

TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $108 from $110 and keeps a Buy rating on the shares. The firm updated its model whil...

Simply Wall St 2d

How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals Investors

Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically...

TipRanks 3d

Ionis Expands Its Rare Epilepsy Pipeline With New ASCEND Trial in Dravet Syndrome

Ionis Pharmaceuticals Inc. (IONS) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, s...

Analyst ratings

79%

of 24 ratings

Buy

79.2%

Hold

20.8%

Sell

More IONS News

The Motley Fool 3d

Ionis Q4 2025 Earnings Transcript

Image source: The Motley Fool. Feb. 25, 2026, 11:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Brett Monia Chief Development Officer — Holly Kordasiew...

TipRanks 3d

Ionis Highlights Positive Zilganersen Data in Alexander Disease

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 4d

Ionis Pharmaceuticals initiated with a Buy at Canaccord

Canaccord initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $110 price target Published first on TheFly – the ultimate source for real-t...

Simply Wall St 7d

A Look At Ionis Pharmaceuticals Valuation After Mixed Recent Share Price Returns

Advertisement Ionis Pharmaceuticals: Recent Returns and Business Profile Ionis Pharmaceuticals (IONS) has seen mixed recent returns, with the stock showing a...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Intel

AMD

Vertex Pharmaceuticals

CrowdStrike Holdings

Taiwan Semiconductor Manu…

Shopify

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.